Kristina Laugesen1, Jens Otto Lunde Jørgensen2, Irene Petersen1,3, Henrik Toft Sørensen1. 1. Department of Clinical Epidemiology, Aarhus University Hospital, Aarhus N, Denmark. 2. Department of Endocrinology and Internal Medicine, Aarhus University Hospital, Aarhus N, Denmark. 3. Department of Primary Care and Population Health, University College London, London, UK.
Abstract
OBJECTIVE: Glucocorticoid treatment of inflammatory disorders is associated with significant adverse effects related to glucocorticoid excess as well as adrenal insufficiency. This necessitates awareness of its use. We therefore investigated trends in systemic glucocorticoid use as well as morbidity and comedications among users. DESIGN: Cross-sectional drug utilisation study. METHODS: We conducted a population-based study of 926,314 users of systemic glucocorticoids (oral and injectable formulations) from 1999 to 2014 using Danish nationwide registries. We computed annual prevalence and incidence of systemic glucocorticoid use and prevalence of comedications and morbidity. Further, we assessed the annual amount of disease-modifying drug use. RESULTS: Of the 926,314 users of systemic glucocorticoids, 54% were female and median age at first-time use was 55 years. The annual prevalence was ≈ 3%, while the incidence was ≈ 1.4/100 person years (p-y). Both figures remained constant from 1999 to 2014. In the elderly, the annual prevalence was 6.7-7.7% (60-79 years of age) and 9.7-11% (≥80 years of age). Incidence increased among persons aged ≥80 years from 3.0/100 p-y in 1999 to 3.6/100 p-y in 2014. Concomitantly, the annual amount of for example methotrexate, azathioprine and tumour necrosis factor (TNF)-alpha agents increased and new biological agents emerged. The most frequent comedications were antibiotics (49%), cardiovascular drugs (38%) and NSAIDs (37%). CONCLUSIONS: Our findings confirm a widespread use of systemic glucocorticoids, especially in the elderly, which prevails despite increased use of disease-modifying drugs. The continuously prevalent use of glucocorticoid use constitutes a challenge for the endocrine community.
OBJECTIVE: Glucocorticoid treatment of inflammatory disorders is associated with significant adverse effects related to glucocorticoid excess as well as adrenal insufficiency. This necessitates awareness of its use. We therefore investigated trends in systemic glucocorticoid use as well as morbidity and comedications among users. DESIGN: Cross-sectional drug utilisation study. METHODS: We conducted a population-based study of 926,314 users of systemic glucocorticoids (oral and injectable formulations) from 1999 to 2014 using Danish nationwide registries. We computed annual prevalence and incidence of systemic glucocorticoid use and prevalence of comedications and morbidity. Further, we assessed the annual amount of disease-modifying drug use. RESULTS: Of the 926,314 users of systemic glucocorticoids, 54% were female and median age at first-time use was 55 years. The annual prevalence was ≈ 3%, while the incidence was ≈ 1.4/100 person years (p-y). Both figures remained constant from 1999 to 2014. In the elderly, the annual prevalence was 6.7-7.7% (60-79 years of age) and 9.7-11% (≥80 years of age). Incidence increased among persons aged ≥80 years from 3.0/100 p-y in 1999 to 3.6/100 p-y in 2014. Concomitantly, the annual amount of for example methotrexate, azathioprine and tumour necrosis factor (TNF)-alpha agents increased and new biological agents emerged. The most frequent comedications were antibiotics (49%), cardiovascular drugs (38%) and NSAIDs (37%). CONCLUSIONS: Our findings confirm a widespread use of systemic glucocorticoids, especially in the elderly, which prevails despite increased use of disease-modifying drugs. The continuously prevalent use of glucocorticoid use constitutes a challenge for the endocrine community.
Authors: Roberta Armignacco; Anne Jouinot; Lucas Bouys; Amandine Septier; Thomas Lartigue; Mario Neou; Cassandra Gaspar; Karine Perlemoine; Leah Braun; Anna Riester; Fidéline Bonnet-Serrano; Anne Blanchard; Laurence Amar; Carla Scaroni; Filippo Ceccato; Gian Paolo Rossi; Tracy Ann Williams; Casper K Larsen; Stéphanie Allassonnière; Maria-Christina Zennaro; Felix Beuschlein; Martin Reincke; Jérôme Bertherat; Guillaume Assié Journal: Eur J Endocrinol Date: 2022-01-13 Impact factor: 6.664
Authors: Anne-Sophie C A M Koning; Philippe C Habets; Marit Bogaards; Jan Kroon; Hanneke M van Santen; Judith M de Bont; Onno C Meijer Journal: Endocr Connect Date: 2022-03-14 Impact factor: 3.335
Authors: Kristina Laugesen; Irene Petersen; Lars Pedersen; Finn Breinholt Larsen; Jens Otto Lunde Jørgensen; Henrik T Toft Sørensen Journal: BMJ Open Date: 2019-10-28 Impact factor: 2.692